PharmaCyte Biotech (OTCMKTS:PMCBD) Stock Price Up 0.1% – Still a Buy?

PharmaCyte Biotech Inc (OTCMKTS:PMCBD)’s share price rose 0.1% during mid-day trading on Tuesday . The company traded as high as $0.74 and last traded at $0.7286. Approximately 54,865 shares changed hands during mid-day trading, an increase of 521% from the average daily volume of 8,831 shares. The stock had previously closed at $0.7277.

PharmaCyte Biotech Price Performance

The business’s fifty day moving average is $0.70 and its 200-day moving average is $0.81.

About PharmaCyte Biotech

PharmaCyte Biotech is a clinical‐stage biotechnology company focused on the development and commercialization of targeted cellular therapies for cancer and diabetes. The company’s core technology, Cell-in-a-Box, encapsulates live, genetically modified cells within a proprietary cellulose‐based polymer matrix. This platform is designed to deliver therapeutic agents directly at tumor sites or within the pancreas, with the goal of maximizing efficacy while minimizing systemic side effects.

In its lead oncology program, PharmaCyte is conducting clinical trials for advanced pancreatic cancer, combining Cell-in-a-Box–encased cells with the prodrug ifosfamide.